CJH Stock Overview
Develops, manufactures, and commercializes vaccines in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CanSino Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.20 |
| 52 Week High | HK$4.22 |
| 52 Week Low | HK$1.81 |
| Beta | 0.49 |
| 11 Month Change | 5.26% |
| 3 Month Change | 68.42% |
| 1 Year Change | 2.56% |
| 33 Year Change | -83.16% |
| 5 Year Change | -47.11% |
| Change since IPO | -8.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| CJH | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.4% | 0.8% | 0.8% |
| 1Y | 2.6% | -18.3% | 8.6% |
Return vs Industry: CJH exceeded the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: CJH underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| CJH volatility | |
|---|---|
| CJH Average Weekly Movement | 14.3% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CJH's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CJH's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,149 | Xuefeng Yu | www.cansinotech.com |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
CanSino Biologics Inc. Fundamentals Summary
| CJH fundamental statistics | |
|---|---|
| Market cap | €1.40b |
| Earnings (TTM) | -€95.03m |
| Revenue (TTM) | €98.78m |
8.3x
P/S Ratio-8.6x
P/E RatioIs CJH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CJH income statement (TTM) | |
|---|---|
| Revenue | CN¥748.53m |
| Cost of Revenue | CN¥774.40m |
| Gross Profit | -CN¥25.87m |
| Other Expenses | CN¥694.25m |
| Earnings | -CN¥720.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.91 |
| Gross Margin | -3.46% |
| Net Profit Margin | -96.20% |
| Debt/Equity Ratio | 41.3% |
How did CJH perform over the long term?
See historical performance and comparison